Takeda boosts sales of Lundbeck-developed drug in H1 2021
Takeda's reported revenue, including the sales of the antidepressant Trintellix/Brintellix, which Takeda and Lundbeck market in a collaboration in the US and Japan, grew by 12.8 percent in the first half of the fiscal year.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
In the months spanning April to September, which make up the first half of the staggered fiscal year of 2021, Takeda's revenue has gone up by 12.8 percent compared to the prior Covid-19-affected year, it reports in a press release on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Takeda's new CEO in Denmark wants to hire more people
For subscribers
